Please login to the form below

Not currently logged in
Email:
Password:

New hires at Bristol-Myers Squibb, Acceleron and FerGene

The latest movers in pharma

Bristol-Myers Squibb

Kathryn Metcalfe Bristol-Myers Squibb has announced changes to its leadership team, following the retirement of its current executive vice president of corporate affairs and investor relations John Elicker.

Kathryn Metclafe (pictured left) has been appointed as executive vice president of corporate affairs, effective 6 January 2020, and Tim Power will take on the role of vice president and head of investor relations, effective 31 March 2020 upon Elicker’s retirement.

Metcalfe joins BMS from CVS Health, where she led communications following the company’s acquisition of Aetna, where she was chief communication officer.

At CVS Health, she oversaw all strategic communications, both internal and external, including reputation and crisis management.

Prior to that, she held several senior communications roles, including chief communications officer at Deloitte, as well as senior roles at Novartis, Pfizer and leadership roles at biotech and healthcare communications firms.

Power joined BMS 13 years ago as a director of portfolio and asset strategy. Since then, he has had various roles of increasing responsibility, culminating in his most recent position as lead for investor relations.

Acceleron 

Jay BackstromAcceleron Pharma has poached Jay Backstrom (pictured right) from Celgene, where he worked as chief medical officer.

He has been appointed to the newly created role of head of research and development at the company, and brings almost three decades of global clinical and regulatory experience to Acceleron.

Backstrom initially joined Celgene in 2008 as vice president, clinical R&D, with a focus on haematology and oncology. He later advanced to the position of CMO and head of regulatory affairs.

Prior to Celgene, he served as vice president, global medical affairs and safety at Pharmion. He began his career at Marion Merrell Dow, and continued as part of its successor companies including Hoechst Marion Roussel, and held roles in clinical research and global drug surveillance and pharmacoepidemiology.

FerGene

David Meek FerGene has appointed David Meek (pictured left) as its new chief executive officer, who moves to the company from Ipsen.

Most recently, he served as CEO of Ipsen, and he brings 30 years of industry experience to FerGene.

While at Ipsen, Meek led a growth strategy of financial results and pipeline advancement and transformed the company into a global biopharma leader.

Prior to Ipsen, he held a number of leadership roles, including executive vice president and president of oncology at Baxalta, and chief commercial officer of Endocyte.

He has also served in various executive leadership roles at Novartis Pharma and Novartis Oncology, and he began his career at Johnson & Johnson and Janssen.

Article by
Lucy Parsons

19th December 2019

From: Communique

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...
Clinical trial recruitment on podcasts: is it a good idea?
The pharmaceutical industry is already using social media and search engine advertising for clinical trials, so why not consider podcast platforms too?...
Healthcare in a lockdown
Even if patients are getting enough care during the COVID-19 pandemic, are they getting the right care?...

Infographics